从多发性硬化症患者的医疗系统专业药剂师干预中避免了成本
Darina Georgieva1, Brandon Markley1, Josh DeClercq2
1Department of Pharmaceutical Services.
Journal of managed care & specialty pharmacy
|March 31, 2024
概括
专业药剂师通过干预疾病修饰疗法 (DMT) 来显著降低多发性硬化症 (MS) 的医疗保健成本. 他们的行动防止不适当的处理和相关的下游利用,节省了大量的资金.
科学领域:
- 药物经济学 药物经济学
- 临床药房 临床药房
- 神经学 神经学
背景情况:
- 专业药剂师在管理正在接受疾病修饰疗法 (DMT) 治疗的多发性硬化症 (MS) 患者中发挥着至关重要的作用.
- 他们的干预重点是优化治疗反应和减轻不良影响,这可能导致医疗费用大幅减少.
- 通过停止不适当的疗法和防止下游医疗利用,这些干预措施提供了经济效益.
研究的目的:
- 量化通过专业药剂师在多发性硬化症 (MS) 患者的干预措施来避免的医疗保健成本.
- 本研究旨在确定MS管理中专业化药物护理的经济影响.
主要方法:
- 在范德比尔特MS诊所进行了一项回顾性观察队列研究.
- 分析了2022年2月1日至2022年7月31日期间专业药剂师的干预.
- 一个小组对直接和间接成本规避的干预进行了分类,使用平均批发价格和经概率调整的后果成本计算成本.
主要成果:
- 分析了354名患者的485项干预措施;38名患者的50项干预措施导致了成本避免.
- 估计在六个月内避免的成本从123,733美元到156,265美元不等,主要来自直接成本避免 (138,410美元).
- 干预措施通常涉及安全监测和管理副作用,特别是在复发性复发性多发性硬化症患者中.
结论:
- 在MS中专业药剂师的干预表明了医疗保健成本节省的巨大潜力.
- 这些节约的主要驱动力是防止发放不适当的疾病修饰疗法.
- 这些发现强调了专门制药护理在治疗MS等慢性疾病方面的经济价值.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Methods of Documentation VI: Case Management Model
571
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
571
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
134
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
134
Psychosis: Goals of Pharmacotherapy
125
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
125


